We are delighted to announce that Dr John Buscombe Clinical Lead and Consultant in the Department of Nuclear Medicine, Cambridge University Hospital will receive the Toshiba Mayneord Award following delivery of this Eponymous lecture “Exploring the nature of altheroma in-vivo using PET” at UKRC on Monday 9 June 2014 at 1:30pm.
Dr Buscombe is known for his contributions in clinical practice, education and research.
He was trained in general internal medicine in London and Essex before being trained in Nuclear Medicine at the Middlesex Hospital, London.
When at the Royal Free Hospital in London, he developed one of Europe’s busiest therapeutic nuclear medicine practices. This included the development of directly injectable radiopharmaceuticals into arteries supplying brain and liver tumours. During this time, he was involved in a range of research projects including Phase I and II trials in both diagnostic and therapeutic nuclear medicine as well as acting as principal investigator in international Phase III trials. These trials included the use of Tc-99m MIBI in identifying and risk-stratifying breast cancer and agents for imaging lung cancer and pulmonary emboli as well as radioimmunotherapy of colon cancer and Hodgkin’s lymphoma.
Since 2010 he has been working at Cambridge University Hospital with experience of pre-clinical work and cyclotron-based PET. The focus of these projects has been on the use of C-11 products in identifying sub-centimetre endocrine tumours and also PET imaging of atheroma and cardiovascular inflammation.
He has published over 190 papers in peer-reviewed journals, written or edited six books and written over 40 book chapters. He continues to work for Nuclear Medicine being a Council Member for the British Nuclear Medicine Society twice and has served on the BNMS annual meeting scientific committee for a total of six years.
For the BIR he has co-organised a series of one day seminars covering everything from imaging in AIDS to radionuclide therapy. He has served on the BIR nuclear medicine and radionuclide dosimetry committees being a co-author of the 2011 report on the provision of the molecular radiotherapy in the UK.
